Literature DB >> 3658570

Taurine improves the absorption of a fat meal in patients with cystic fibrosis.

D C Belli1, E Levy, P Darling, C Leroy, G Lepage, R Giguère, C C Roy.   

Abstract

The effect of taurine supplementation on the absorption of a fat meal was evaluated in patients with cystic fibrosis. In a cross-over design study, five patients with cystic fibrosis (12.1 +/- 2.6 years of age) and three control subjects received either placebo or taurine (30 mg/kg/d) for two 1-week periods, a month apart, followed by a fat meal test. Blood samples were drawn 0, 1, 2, 3, 5, 8 hours after the meal. Four patients with cystic fibrosis and severe steatorrhea despite appropriate enzyme therapy showed a significant (P less than .05) improvement in the absorption of triglycerides, total fatty acids, and linoleic acid while receiving taurine supplements. Three control subjects and one child with cystic fibrosis and mild steatorrhea receiving enzyme therapy did not experience such an effect. The difference in triglyceride absorption, when calculated as the area under the curve, receiving and not receiving taurine was significantly (P less than .05) correlated with the degree of steatorrhea. Furthermore, in contrast to control subjects, the fatty acid composition of chylomicrons in these four study patients showed important discrepancies with that of the fat meal and was corrected, in part, by taurine supplementation. These results suggest that taurine supplementation could be a useful adjunct in the management of patients with cystic fibrosis with ongoing fat malabsorption and essential fatty acid deficiency.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3658570

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

Review 1.  A rational approach to the nutritional care of patients with cystic fibrosis.

Authors:  P R Durie; P B Pencharz
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 2.  Cystic fibrosis.

Authors:  T J David
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

Review 3.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

4.  Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations.

Authors:  K H Hsieh; M F Shaio; T N Liao
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

Review 5.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2020-03-30

6.  Effect of taurine supplementation on fat and energy absorption in cystic fibrosis.

Authors:  M De Curtis; F Santamaria; P Ercolini; L Vittoria; G De Ritis; V Garofalo; F Ciccimarra
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

Review 7.  Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.

Authors:  Adriana Haack; Giselle Gonçalves Aragão; Maria Rita Carvalho Garbi Novaes
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

8.  Mechanisms of lipid malabsorption in Cystic Fibrosis: the impact of essential fatty acids deficiency.

Authors:  N Peretti; V Marcil; E Drouin; E Levy
Journal:  Nutr Metab (Lond)       Date:  2005-05-03       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.